Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer.
- Published In:
- Acta pharmacologica Sinica, 46(12), 3291-3301 (2025)
- Authors:
- Bo, Qing, Zhang, Meng-Ge, Yang, Fan(4), Zheng, Yong, Li, Ze-Lin, Zheng, Yan-Min, Wu, Fang-Ming, Liang, Jun, Zhou, Li, Li, Dong-Sheng, Wu, Yun, Tian, Chang-Lin, Lv, Pei, Shi, Pan
- Database ID:
- RPEP-10182
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10182APA
Bo, Qing; Zhang, Meng-Ge; Yang, Fan; Zheng, Yong; Li, Ze-Lin; Zheng, Yan-Min; Wu, Fang-Ming; Liang, Jun; Zhou, Li; Li, Dong-Sheng; Wu, Yun; Tian, Chang-Lin; Lv, Pei; Shi, Pan. (2025). Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer.. Acta pharmacologica Sinica, 46(12), 3291-3301. https://doi.org/10.1038/s41401-025-01584-w
MLA
Bo, Qing, et al. "Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer.." Acta pharmacologica Sinica, 2025. https://doi.org/10.1038/s41401-025-01584-w
RethinkPeptides
RethinkPeptides Research Database. "Somatostatin receptor 2 targeting peptide modifications for ..." RPEP-10182. Retrieved from https://rethinkpeptides.com/research/bo-2025-somatostatin-receptor-2-targeting
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.